Clinical Trials Logo

Citation(s)

  •   Brater DC
    Update in diuretic therapy: clinical pharmacology. Semin Nephrol. 2011 Nov;31(6):483-94. doi: 10.1016/j.semnephrol.2011.09.003. Review.
  •   Costa-Rodrigues J, Reis S, Teixeira S, Lopes S, Fernandes MH
    Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity. FEBS J. 2013 Oct;280(20):5052-64. doi: 10.1111/febs.12478. Epub 2013 Sep 5.
  •   Delomenède M, Buchet R, Mebarek S
    Lansoprazole is an uncompetitive inhibitor of tissue-nonspecific alkaline phosphatase. Acta Biochim Pol. 2009;56(2):301-5. Epub 2009 Jun 18.
  •   Donos N, Calciolari E
    Dental implants in patients affected by systemic diseases. Br Dent J. 2014 Oct;217(8):425-30. doi: 10.1038/sj.bdj.2014.911. Review.
  •   Gasiorowska A, Fass R
    The proton pump inhibitor (PPI) test in GERD: does it still have a role? J Clin Gastroenterol. 2008 Sep;42(8):867-74. doi: 10.1097/MCG.0b013e31816c47ed. Review.
  •   Haney EM, Warden SJ
    Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact. 2008 Apr-Jun;8(2):133-45. Review.
  •   Lisowska B, Kosson D, Domaracka K
    Positives and negatives of nonsteroidal anti-inflammatory drugs in bone healing: the effects of these drugs on bone repair. Drug Des Devel Ther. 2018 Jun 21;12:1809-1814. doi: 10.2147/DDDT.S164565. eCollection 2018. Review.
  •   Mattsson JP, Väänänen K, Wallmark B, Lorentzon P
    Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta. 1991 Jun 18;1065(2):261-8.
  •   Mizunashi K, Furukawa Y, Katano K, Abe K
    Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993 Jul;53(1):21-5.
  •   Mombelli A, Cionca N
    Systemic diseases affecting osseointegration therapy. Clin Oral Implants Res. 2006 Oct;17 Suppl 2:97-103. Review. Erratum in: Clin Oral Implants Res. 2006 Dec;17(6):746.
  •   Rice JB, White AG, Scarpati LM, Wan G, Nelson WW
    Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. Clin Ther. 2017 Nov;39(11):2216-2229. doi: 10.1016/j.clinthera.2017.09.011. Epub 2017 Oct 19. Review.
  •   Roberts S, Narisawa S, Harmey D, Millán JL, Farquharson C
    Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization. J Bone Miner Res. 2007 Apr;22(4):617-27.
  •   Rodan GA, Martin TJ
    Therapeutic approaches to bone diseases. Science. 2000 Sep 1;289(5484):1508-14. Review.
  •   Schoenfeld DA
    Sample-size formula for the proportional-hazards regression model. Biometrics. 1983 Jun;39(2):499-503.
  •   Schweiger U, Weber B, Deuschle M, Heuser I
    Lumbar bone mineral density in patients with major depression: evidence of increased bone loss at follow-up. Am J Psychiatry. 2000 Jan;157(1):118-20.
  •   Vestergaard P
    Skeletal effects of central nervous system active drugs: anxiolytics, sedatives, antidepressants, lithium and neuroleptics. Curr Drug Saf. 2008 Sep;3(3):185-9. Review.
  •   Ye X, Liu H, Wu C, Qin Y, Zang J, Gao Q, Zhang X, He J
    Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2011 Sep;23(9):794-800. doi: 10.1097/MEG.0b013e328348a56a. Review.
  •   Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E, Bauer DC
    Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008 Oct;83(4):251-9. doi: 10.1007/s00223-008-9170-1. Epub 2008 Sep 24.

Correlation Between Peri-implantitis and Assumptions of Medications: a Retrospective Study

Details for clinical trial NCT04783974